Kevin P. Starr, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 90,000 shares at $77.48 ($7.0M) on 2014-09-24, disclosed to the SEC on 2014-09-26.
Scheduled sale ($7.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $77.48 | 3,700 | $287K | 4.1% |
| 2 | $78.68 | 12,375 | $974K | 13.9% |
| 3 | $79.45 | 28,925 | $2.3M | 32.7% |
| 4 | $76.36 | 7,399 | $565K | 8.0% |
| 5 | $77.13 | 34,201 | $2.6M | 37.5% |
| 6 | $78.30 | 2,500 |
| $196K |
| 2.8% |
| 7 | $79.10 | 900 | $71K | 1.0% |
| Total | $78.09 avg | 90,000 | $7.0M | 100% |
| Filing → |
| FULC | BUY | 2019-07-22 | $1.3M | — | Filing → |
| SAGE | SELL | 2018-04-19 | $10.0M | — | Filing → |
| MYOK | SELL | 2018-01-05 | $34.3M | — | Filing → |